Headquartered in Princeton, NJ Fiscal year ends December NYSE: BMY bms.com
Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops and markets prescription medicines for serious diseases. It sells into the U.S. and international markets, with the U.S. accounting for the majority of revenue.
It reports products in two groups:
- **Growth Portfolio:** mostly medicines early in their lifecycles.
- Oncology: Opdivo, Opdivo Qvantig, Yervoy, Opdualag, Krazati, Augtyro.
- Hematology and cell therapy: Reblozyl, Breyanzi, Abecma, the newly approved CELMoD Zenbexus.
- Cardiovascular: Camzyos.
- Immunology: Orencia, Zeposia, Sotyktu.
- Neuroscience: Cobenfy.
- Royalty revenues, including royalties from Merck on Winrevair.
- **Legacy Portfolio:** led by the anticoagulant Eliquis, plus Revlimid, Pomalyst/Imnovid, Sprycel and Abraxane, which face generic erosion.
The company also has radiopharmaceutical capabilities through its RayzeBio subsidiary. Its late-stage pipeline spans:
- CELMoDs: mezigdomide, golcadomide.
- Cell therapies: arlo-cel, zola-cel.
- Bispecifics and ADCs: pumitamig, iza-bren.
- Other programs: milvexian, admilparant, RYZ101.
It is expanding its U.S. manufacturing footprint and uses licensing and business development to supplement internal R&D. Updated
The first profitable quarter in two years rests on licensing: a $613 million recognition on the Bristol Myers Squibb pumitamig deal carried the beat. Track the oncology launch timeline rather than the headline numbers.
Bristol Myers Squibb cut full-year adjusted EPS guidance to $6.35 to $6.55 from $6.75 to $7.00 even though both lines topped expectations, a split driven by acquired IPRD charges while the revenue outlook went up. Keep an eye on the stock as investors weigh the dealmaking hit.
Defense and big pharma own the top of the board at the open, led by Northrop Grumman up 5.36%, with Eli Lilly, Bristol-Myers Squibb and Merck also higher. The pain is concentrated in crypto miners and optics names, where IREN leads the decline.
Every one of today's five worst performers in a 383-name universe lost double digits, led by CoreWeave's 15.42% drop. The best gain on the other side was capped at 4.62%, so the downside is moving far faster than the upside.
A 4.10% intraday move to $58.90 adds roughly $5 billion to a $120 billion drugmaker, and big pharma rarely travels that far in a single session. Worth seeing whether the gain holds into the close.
A 4.29% slide to $57.23 is an outsized single session for a $117 billion pharma name that usually trades like a bond proxy. Dividend buyers watching for an entry get a cheaper one today.
Both Petrobras lines closed double digits higher, the only names in a 383-stock board to do it. MercadoLibre and Tempus AI each added more than 9%, while the worst loser gave up under 5%, so the upside skew was lopsided.
Recessions punish shaky payouts, but some companies keep collecting cash anyway. From power lines to pipelines to pill bottles, five low-beta names promise income, yet one of them runs coverage tighter than…
A blockbuster blood thinner is about to lose $1.5 billion to $2 billion in sales, and the debt pile hasn't gone away. Retirees counting on Bristol Myers Squibb's payout need to know…
AbbVie just logged a 33% gain for the year and raised its guidance again, but the real question is whether Skyrizi and a newly closed pipeline deal can push shares even further…
Pfizer's dividend yield sits near 6%, but the company paid out more in dividends last year than it generated in free cash flow. Before income investors panic or pile in, the real…
Merck (NYSE:MRK | MRK Price Prediction) is the second big drugmaker to reward investors with an earnings beat and a raised profit outlook. However, Merck’s steady, Keytruda-anchored growth tells a very different…
Where you hold a dividend stock matters almost as much as which one you pick, and three blue-chip payers reveal exactly how much the IRS quietly collects each year depending on your…
Moderna‘s (NASDAQ:MRNA | MRNA Price Prediction) push into cancer treatment is drawing heavy buying as a closely followed melanoma presentation approaches. Shares of Moderna are up 7% to $241.89 during the trading…
Pfizer's 5.8% yield looks tempting until you check what the dividend is actually costing the company relative to its cash generation. The math behind that payout is more uncomfortable than the headline…
AbbVie's stock has surged nearly 29% this year, but a rising share price compresses the yield even as the dividend keeps growing. Before adding shares for income, consider what the pending Apogee…
Bristol Myers Squibb has raised its dividend for 17 straight years, but a looming patent cliff and $43 billion in debt put the pace of future increases on a collision course with…
Six popular dividend stocks sitting in a taxable account quietly hand a portion of every payout to the IRS, and the gap between what you earn and what you keep widens sharply…
Four companies kept raising their dividends even as the pandemic hammered their sectors in 2020, and they are still raising today. The question is whether their yields and valuations make them worth…
Every big pharma company eventually watches its best-selling drug go generic, yet some keep raising their dividends anyway. The five names on this list have already replaced their fading blockbusters with something…
Pfizer's dividend yield has climbed well above what most blue-chip drugmakers offer, and the reason behind that gap matters far more than the number itself.
A fat dividend yield means nothing if the cash runs dry before the check clears. These five companies show wildly different margins of safety, and one of them barely cleared the bar…
Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops and markets prescription medicines for serious diseases. It sells into the U.S. and international markets, with the U.S. accounting for the majority of revenue.
24/7 Wall St.'s 12-month price target for BMY is $75.23, rated Buy. The Wall Street consensus target is $65.25. BMY price prediction →
